16th Apr 2015 13:28
LONDON (Alliance News) - AstraZeneca PLC said Thursday that its biologics research and development arm MedImmune is collaborating with UK biotechnology company Immunocore Ltd to conduct clinical trials in melanoma.
Under the agreement, Immunocore will conduct a phase IB/II trial combining MedImmune's MEDI4736 and or tremelimumab with its T-cell receptor based investigation therapeutic IMCgp100 in metastatic melanoma.
MedImmune has an exclusive deal with Immunocore for the development of IMCgp100 in these combinations, and will have first right of negotiation for the future development of these combinations for tumours expressing the antigen glycoprotein 100.
The two companies entered into a collaboration and licensing deal last January, to develop cancer treatments using Immunocore's monoclonal T-cell receptor against cancer technology, or ImmTAC.
Shares in AstraZeneca are trading up 0.3% at 4,872.00 pence Thursday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca